Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Braxia Scientific Corp C.BRAX

Alternate Symbol(s):  BRAXF

Braxia Scientific Corp. is a Canada-based medical research and telemedicine company with a clinic that provide ketamine treatments for persons with depression and related disorders. Through its medical solutions, it intends to reduce the illness burden of brain-based disorders, such as major depressive disorder, among others. The Company is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. It seeks to develop ketamine and derivatives and other psychedelic products from its IP development platform. The Company has clinic operations in the Canadian cities of Mississauga, Kitchener-Waterloo, Ottawa and Montreal. Its subsidiary, Braxia Health, is engaged in offering rapid onset treatments to aid those suffering from several treatment-resistant conditions, such as depression and bipolar disorder.


CSE:BRAX - Post by User

Comment by DustinFon Sep 28, 2020 6:16pm
307 Views
Post# 31632946

RE:RE:RE:RE:RE:RE:RE:RE:RE:SHRMF Back from dead?

RE:RE:RE:RE:RE:RE:RE:RE:RE:SHRMF Back from dead?
I was saying this was going to the deep end late March at $1.85 due to their current financial status. All i recieved was rederict from people too emotionally attached to their investments. At .89 their market cap is $70m with no reason to believe it's even worth that much. They most certainly have potential but are far(years away)from being worth even that much of value. They barely have any income. In the future they might, but that requires so much more progress that currently isnt materializing(that we are aware of). Considering how expensive their treatments will be, and who knows if any government funds will help assist patients in these treatments, covid will only be a set back. People can't afford >1.5k a treatment. This company does have potential and i think the legalization of medicinal psychedelics has the potential to truly be a game changer. This company has a long way to go before they can make any ground financially(which will ultimately bring shareholder value). I would love to invest in this sector but i fail to see any potential profits with ketamine, or psilocybin possibly until the 2030's.
<< Previous
Bullboard Posts
Next >>